Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) Set to Announce Quarterly Earnings on Wednesday
Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) is set to announce its earnings results after the market closes on Wednesday, August 2nd. Analysts expect the company to announce earnings of ($0.28) per share for the quarter.
Vanda Pharmaceuticals (NASDAQ:VNDA) last announced its quarterly earnings data on Tuesday, May 2nd. The biopharmaceutical company reported ($0.17) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.13) by $0.04. Vanda Pharmaceuticals had a negative net margin of 8.85% and a negative return on equity of 10.42%. The firm had revenue of $37.42 million for the quarter, compared to analysts’ expectations of $38.35 million. On average, analysts expect Vanda Pharmaceuticals to post $-0.70 EPS for the current fiscal year and $-0.33 EPS for the next fiscal year.
Shares of Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) opened at 16.05 on Wednesday. The stock’s market capitalization is $715.06 million. Vanda Pharmaceuticals Inc. has a 12 month low of $10.98 and a 12 month high of $18.00. The company’s 50-day moving average is $15.54 and its 200 day moving average is $14.55.
TRADEMARK VIOLATION WARNING: “Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) Set to Announce Quarterly Earnings on Wednesday” was posted by American Banking News and is owned by of American Banking News. If you are reading this news story on another website, it was illegally stolen and reposted in violation of U.S. and international trademark & copyright law. The legal version of this news story can be read at https://www.americanbankingnews.com/2017/07/26/vanda-pharmaceuticals-inc-nasdaqvnda-set-to-announce-quarterly-earnings-on-wednesday.html.
VNDA has been the subject of a number of recent research reports. Zacks Investment Research upgraded shares of Vanda Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Wednesday, June 14th. TheStreet upgraded shares of Vanda Pharmaceuticals from a “d+” rating to a “c-” rating in a report on Friday, May 12th. CIBC reiterated an “outperform” rating and issued a $21.00 target price on shares of Vanda Pharmaceuticals in a report on Wednesday, April 12th. Oppenheimer Holdings, Inc. initiated coverage on shares of Vanda Pharmaceuticals in a report on Wednesday, April 12th. They issued an “outperform” rating and a $21.00 target price for the company. Finally, Piper Jaffray Companies reiterated an “overweight” rating and issued a $23.00 target price on shares of Vanda Pharmaceuticals in a report on Tuesday, June 27th. One research analyst has rated the stock with a sell rating and eight have issued a buy rating to the company’s stock. The stock currently has an average rating of “Buy” and a consensus target price of $21.22.
About Vanda Pharmaceuticals
Vanda Pharmaceuticals Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapies to address unmet medical needs. Its product portfolio includes HETLIOZ (tasimelteon), Fanapt (iloperidone), Tradipitant (VLY-686), Trichostatin A and AQW051. It offers HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24).
Receive News & Ratings for Vanda Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vanda Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.